Cerus Corporation
$ 2.56
1.79%
11 Aug - close price
- Market Cap 507,843,000 USD
- Current Price $ 2.56
- High / Low $ 2.65 / 2.51
- Stock P/E N/A
- Book Value 0.35
- EPS -0.03
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA N/A %
- ROE -0.11 %
- 52 Week High 3.47
- 52 Week Low 1.15
About
Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in Concord, California.
Analyst Target Price
$4.50
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-30 | 2026-04-30 | 2026-03-02 | 2025-11-06 | 2025-08-05 | 2025-05-01 | 2025-02-20 | 2024-10-30 | 2024-08-01 | 2024-05-02 | 2024-03-05 | 2023-11-02 |
| Reported EPS | -0.01 | -0.01 | -0.01 | -0.0001 | -0.03 | -0.04 | -0.01 | -0.02 | -0.03 | -0.05 | -0.01 | -0.03 |
| Estimated EPS | -0.01 | -0.04 | -0.0075 | -0.02 | -0.02 | -0.05 | -0.01 | -0.03 | -0.04 | -0.04 | -0.02 | -0.05 |
| Surprise | 0 | 0.03 | -0.0025 | 0.0199 | -0.01 | 0.01 | 0 | 0.01 | 0.01 | -0.01 | 0.01 | 0.02 |
| Surprise Percentage | 0% | 75% | -33.3333% | 99.5% | -50% | 20% | 0% | 33.3333% | 25% | -25% | 50% | 40% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CERS
2026-08-08 00:39:45
This page provides the latest news and information for Cerus Corp (CERS) stock on TradingKey, a financial information platform. As of August 7th, Cerus Corp's stock closed at $2.350, up 1.29%. The platform also offers an overview, news and analysis, financial data, stock score, technical forecast, ownership details, dividends, and profile information for CERS.
2026-08-07 08:10:28
Cerus Corp (CERS) has an earnings forecast score of 8.67, ranking 17th in its industry, with an average analyst price target of $5.00, suggesting a 113.09% upside. Based on 3 analysts, the stock is rated as a "Buy." The company's expected revenue for the next quarter is $61.60 million, and its EPS for the previous and next quarters is estimated at -$0.01.
2026-08-02 13:40:54
Cerus Corp (CERS) reported its second-quarter 2026 results, showing revenue of $57.4 million, an increase from $52.4 million in the prior year. The company also narrowed its net loss to $(2.94) million from $(5.71) million, and its diluted loss per share improved to $(0.01) from $(0.03) year-over-year. Key highlights included a 10% rise in product revenue driven by increased disposable platelet/plasma kit and IFC sales in the U.S., progress in Phase 3 trials for the red blood cell system, and expanding global adoption of its products.
2026-08-02 12:36:46
Cerus Corporation (CERS) stock has dropped significantly by 23.88% due to adverse regulatory news and increased bearish sentiment. The company, which operates in blood safety, shows solid revenue growth but remains unprofitable, making it a high-risk, high-reward stock for traders. Analysts note its adequate liquidity but elevated leverage, suggesting a challenging path to sustainable profitability, with traders focusing on whether current price levels will form a base or lead to further decline.
2026-07-30 22:11:02
Cerus (NASDAQ:CERS) announced its earnings results, meeting analyst expectations with a quarterly loss of $0.01 per share and revenue of $63.3 million, slightly above the $62.9 million forecast. The company reported a 10% increase in product revenue to $57.4 million, driven by significant growth in INTERCEPT fibrinogen complex revenue, and raised its 2026 product revenue guidance. Despite a decline in gross margin and negative operating cash flow, Cerus refinanced its debt and submitted its INT200 platelet application to the FDA, with potential approval in early 2027.
2026-07-30 21:11:01
Cerus Corporation reported Q2 2026 results that surpassed analyst estimates for both profit and revenue, with an adjusted EPS loss of $0.01 against an expected loss of $0.03, and revenue of $63.3 million compared to a $62.9 million forecast. Despite the beat and raised full-year product revenue guidance, the company's shares dropped 15.21% in after-hours trading, likely due to investor concerns over margin pressure and negative operating cash flow. The blood-safety company highlighted strong product revenue growth, particularly from its U.S. IFC franchise, and continued progress towards GAAP profitability.
